Everest Medicines News and Activities
Presence
Headquarters: United States (USA)
Acquisition, funding and merger involving Everest Medicines.
- Everest Medicines has just announced a $200 Million fundraising (posted on July 28 2025).
Executives
View the org chart displaying its 23 main executives
Most searched biographies at Everest Medicines
- Rogers Yongqing Luo, Chief Executive Officer
- Harry Sun, Non-Executive Director
- Yifang Wu, Chairman of the Board
Popular executive movements at Everest Medicines
- Yifang Wu has joined the company as Chairman of the Board (posted on October 10 2025).
- Wei Fu, Chairman of the Board, has left the company (posted on October 10 2025).
Create your alert
to follow the executive moves at Everest Medicines.
Pharmaceuticals
Everest Medicines has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Everest Medicines
- Everest Medicines Announces the Launch of VELSIPITY® in the Guangdong-Hong Kong-Macau Greater Bay Area, Offering a New Option for Moderately to Severely Active Ulcerative Colitis Patients – Everest Medicines
- Everest Medicines Announces the Launch of VELSIPITY® in the Guangdong-Hong Kong-Macau Greater Bay Area, Offering a New Option for Moderately to Severely Active Ulcerative Colitis Patients – Everest Medicines
- Everest Medicines Announces Taiwan TFDA Approval of NEFECON® for the Treatment of Primary IgA Nephropathy – Everest Medicines
- Everest Medicines Announces Positive Results of Complete Chinese Subpopulation Data from the NEFECON® Global Phase 3 NefIgArd Clinical Trial Published in “Kidney 360” Magazine – Everest Medicines
- Everest Medicines Announces Taiwan TFDA Approval of NEFECON® for the Treatment of Primary IgA Nephropathy – Everest Medicines
- Everest Medicines Announces Positive Results of Complete Chinese Subpopulation Data from the NEFECON® Global Phase 3 NefIgArd Clinical Trial Published in “Kidney 360” Magazine – Everest Medicines
- Everest Medicines Announces Attendance at the Following September Investor Conferences – Everest Medicines
- Everest Medicines Announces Interim Results for First Half of 2024 – Everest Medicines
- Everest Medicines Announces Interim Results for First Half of 2024 – Everest Medicines
- Everest Medicines Announces the Initiation of an Investigator-Initiated Clinical Trial (IIT) for Personalized mRNA Cancer Vaccine Program EVM16 – Everest Medicines
- View more press releases Close
Social media about Everest Medicines
- Everest Medicines on Wikipedia, Google News & Yahoo Finance
- Everest Medicines on LinkedIn, X (Twitter) & YouTube
